Navigation Links
Aviir Laboratories Announce National Agreement With MultiPlan
Date:4/25/2012

IRVINE, Calif., April 25, 2012 /PRNewswire/ -- Aviir Diagnostic Laboratory announced today that it has entered into a contractual agreement with MultiPlan, Inc. for ancillary diagnostics laboratory testing. The agreement includes Aviir's participation in the MultiPlan, PHCS and PHCS Savility Networks.

Aviir was founded in 2005 by cardiologists and scientists from the Stanford University School of Medicine to focus on discovery, development and commercialization of innovative diagnostic tests. The biotechnology company specializes in developing proprietary diagnostic tests that will assist in identifying patients who are truly at high risk for the development of a cardiac event. Aviir's proprietary MiRisk™ and TruRisk™ assessments objectively identify, by a simple blood draw, individuals who are at a high risk of a cardiac event over the next five years. Aviir's CLIA laboratory (Irvine, CA) complements these novel tests with a wide range of additional tests for risk assessment and therapeutic monitoring of cardiovascular disease and related metabolic disorders – including pharmacogenomics and genetic tests. www.aviir.com

Aviir's agreement with MultiPlan will give MultiPlan's participating providers and its clients' members access to Aviir's tests. Approximately 900,000 providers participate in MultiPlan's provider networks and an estimated 57 million consumers have access to one or more of these networks.

"There is currently a significant yet unmet clinical need in the medical community for more effective ways to identify individuals at high risk of a heart attack who are missed by current evaluation methods. Providing an accurate assessment of the patient's overall heart health is the first step in prevention of cardiovascular disease," stated Douglas Harrington, M.D., Chief Executive Officer of Aviir. "Our agreement with MultiPlan will help ensure more doctors and therefore patients have access to the tools that can provide the accurate assessment."

"At Aviir, our ultimate goal is to help physicians identify those patients who are at serious risk of experiencing a heart attack but are completely unaware of their precarious condition. Armed with better information, physicians will be able to customize individualized treatment plans with the goal of improving patient therapeutic compliance, reduce their risk of heart attacks, and decrease the overall cost of care." Dr. Harrington added.

Learn more about Aviir at www.aviir.com.

Learn more about MultiPlan at www.multiplan.com.

For more information:
Dina Scaglione
(949) 910-9401
dina.scaglione@aviir.com


'/>"/>
SOURCE Aviir Diagnostic Laboratory
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Aviir Diagnostics Laboratory in Collaboration with Cause;ology Sponsors "Storyland," a Red Carpet Charity Extravaganza in Hollywood
2. MO BIO Laboratories, Inc. Launches the PowerMicrobiome™ RNA Isolation Kit
3. ARUP Laboratories Announces Creation of Business Innovations Division
4. EMD Millipore Partners with Charles River Laboratories for Improved Viral Clearance Studies
5. John Saltamartine to Lead Operations as VR Laboratories Chief Operating Officer
6. ARUP Laboratories Pathologist, Ronald L. Weiss, MD, Honored With Lifetime Achievement Award for Contributions to Patient Care and Pathology
7. IDEXX Laboratories Acquires the RADIL Reference Laboratory from the University of Missouri
8. VetNostic Laboratories® Announces New Testing for Dog Breeds
9. Access Medical Laboratories, Inc. to Celebrate Grand Opening of New Laboratory Headquarters in Jupiter, Florida
10. Building, Validating & Maintaining Controlled Environment Facilities is Focus of Oct. 18th Seminar in Boston Hosted by Microtest Laboratories
11. MO BIO Laboratories, Inc. Launches the RTS DNase™ Kit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... and BEIJING , Nov. 30, 2016 ... provider of genomic services and solutions with cutting edge ... it has completed a USD $75 Million [515 Million ... Ltd.,s CMB International Capital Management ( Shenzhen ... Co., Ltd. ("SDIC Innovation") and Shanghai Sigma Square Investment ...
(Date:11/30/2016)... 30, 2016   Merck , a leading science ... into a set of agreements with Evotec AG, whereby ... of genetic reagents such as CRISPR and shRNA libraries. ... offers an accelerated pathway to explore and identify new ... identification of new targets, a process that can be ...
(Date:11/30/2016)... Park, NC (PRWEB) , ... November 30, 2016 ... ... company engaged in the development of a new orally administered treatment for Alzheimer’s ... and neuroimaging results of a Phase 2a clinical trial of T3D-959 in mild ...
(Date:11/30/2016)... Toronto, ON (PRWEB) , ... November 30, 2016 ... ... focused on discovery and development of precision treatments for neurodegenerative diseases, today announced ... disease (AD) (announced on November 3, 2016) blocked propagation of toxic, prion-like forms ...
Breaking Biology Technology:
(Date:11/21/2016)...   Neurotechnology , a provider of high-precision ... that the MegaMatcher On Card fingerprint matching algorithm ... NIST Minutiae Interoperability Exchange (MINEX) III ... of the evaluation protocol. The ... fingerprint templates used to establish compliance of template ...
(Date:11/17/2016)... 2016 Global Market Watch: Primarily supported ... Population-Based Banks and Academics) market is to witness a value ... shows the highest Compounded Annual Growth Rate (CAGR) of 10.75% ... the analysis period 2014-2020. North America ... by Europe at 9.56% respectively. ...
(Date:11/16/2016)... , Nov. 16, 2016 Sensory Inc ... and security for consumer electronics, and VeriTran ... and retail industry, today announced a global partnership ... way to authenticate users of mobile banking and ... TrulySecure™ software which requires no specialized biometric ...
Breaking Biology News(10 mins):